The article discusses the pathogenetic and clinical aspects of gastrointestinal bleeding (GIB) in patients with a novel coronavirus infection (COVID-19). The possibility of direct interaction of the coronavirus with the receptors of the angiotensinconverting enzyme 2 (ACE-2) of the mucous membrane of the gastrointestinal tract with the development of its damage and subsequent bleeding has been shown. The value of anticoagulant therapy as a risk factor for the occurrence of GIB is evaluated inconsistently. In most patients with COVID-19 infection and GIB conservative hemostatic therapy is eff ective. The infl uence of GIB on the course and prognosis of a novel coronavirus infection has an contradictory interpretation. Given the lack of knowledge of the pathogenetic and clinical aspects of GIB in patients with COVID-19 infection, this problem requires further research.